Grappa « difficult to treat and complex to manage» PsA meeting - SLR, Patient & rheumo survey, working on definition eg - fail 1 csDMARD & 2 bDMARDs different MOA @RheumNow #EULAR2024

PRO-SPIRIT 1100+ PsA Observational study IXE i= TNFi and JAKi for improving joint dis activity in IXE higher previous b/tsDMARD & less concomitant csDMARDs IXE & IL-17Ai = faster improvement cDAPSA than IL-12/23i or IL-23i Abst LBA0002 #EULAR2024 @RheumNow https://t.co/8DbtCQECNN

• https://twitter.com/AurelieRheumo/status/1801895455757852889/photo/1

EFFICACY & SAFETY OF IZOKIBEP, A NOVEL IL-17A INHIBITOR, IN PATIENTS WITH ACTIVE PSA: WEEK 16 RESULTS FROM A RANDOMIZED, DB,PBO CONTROLLED, MULTICENTER 2b/3 STUDY ACR responses 60:40:20 42% MDA PASI 100 47% ho hum same as others-how many IL17s do we need ? @RheumNow #EULAR2024

POS0231 Safety of JAKi vs TNFi or IL-17 inhibitors in #PsA & #SpA Results from a large population-based study show reassuring data, with no increased risk of #CVD, #VTE or certain cancers compared to TNFi or IL-17i @SteZhao @RheumNow #EULAR2024

1200 PsA pts 6 countries IL17is as effective as TNFi and JAK despite more failed bDMARDs and monotherapy & faster onset action than IL23s ⁦@RheumNow⁩ #EULAR2024 https://t.co/SM5CA7KUvd

• https://twitter.com/drpnash/status/1801879213739237768/photo/1

#EULAR2024 LBA0009 Phase 3 Open label H2H RCT of Ixekizumab vs in jPsA & enthesitis-related arthritis showed similar ACR30 response rates at Wk16 (IXE=89%; ADA=95%). Open label and long-term follow up for IXE is ongoing to assess for sustainment @RheumNow https://t.co/lk42I7Mn8B

• https://twitter.com/Yuz6Yusof/status/1801876904506478640/photo/1
• https://twitter.com/Yuz6Yusof/status/1801876904506478640/photo/1

Cohort from Netherlands 400+ PsA pts IR first bioDMARD 300+ switched TNFi->IL-17i, 99 cycled TNFi->TNFi 3year retention rates 12 mo 75% cyclers 80% swappers 24mo 60% cyclers 56% swappers No difference in treatment failure or DAS28 CRP #EULAR2024 @RheumNow POS0278 https://t.co/J8ONjVAFqG

• https://twitter.com/AurelieRheumo/status/1801520487605911565/photo/1

EFFICACY AND SAFETY OUTCOMES OF TAK-279, A SELECTIVE ORAL TYROSINE KINASE 2 (TYK2) INHIBITOR, FROM A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2B TRIAL IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS - smells tastes & looks like a Tyk2 - acne signal? @rheumnow #EULAR2024